Genentech/Curis To Reformulate Basal Cell Carcinoma Topical Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary Phase I results show histological clearance, but less clinical activity than anticipated with Hedgehog antagonist, Curis says.
You may also be interested in...
Curis To Continue Focus On Oncology After Wyeth Ends Hedgehog Venture
Cambridge, Mass.-based Curis seeks a new partner to continue small molecule and protein hedgehog agonist development in cardiovascular/nervous system disorders.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.